Athithi Verma

With a sharp lens on biopharma innovation and market-defining trends, Athithi delivers content that cuts through noise and gets to the signal. At Synopulse, she brings narrative command and analytical fluency, transforming technical developments into stories that inform, challenge, and resonate.

Bain Capital Acquires Mitsubishi Tanabe Pharma

by

Bain Capital, a leading global private investment firm with approximately $160 billion in assets under management, has announced its agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC), a renowned Japanese pharmaceutical company with over 300 years of heritage. This transaction represents one of Bain Capital’s largest investments in the pharmaceutical sector and demonstrates its continued … Read more

Eli Lilly Shakes Up JPM25 with $2.5B Scorpion Buyout in Breast Cancer Battle

by

Eli Lilly kicked off the 2025 J.P. Morgan Healthcare Conference with a strategic acquisition of Scorpion Therapeutics, securing its PI3Kα pipeline for up to $2.5 billion in upfront payments and milestones. The deal marks a bold move in Lilly’s quest to compete with Novartis and Roche in the lucrative breast cancer market. A Renewed Push … Read more

GSK snaps up IDRx for up to $1.15B

by

Britan-based pharmaceutical giant GSK has agreed to acquire 100% of the outstanding equity interests (including all options and other incentive equity) in IDRx, a US-based, clinical-stage biopharmaceutical company focused on developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). The acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) being developed … Read more

Pfizer picks Triana Biomedicines to find Molecular Glues for Cancer

by

US pharmaceutical giant Pfizer announced a groundbreaking collaboration with Triana Biomedicines to develop Molecular Glue Degraders. The partnership aims to create multiple advanced therapies, including cancer. The collaboration is seen as a significant step forward in developing advanced medical treatments that can address challenging disease targets.  Targeted protein degradation is a novel and fast-growing segment. … Read more

OncoC4 merged with AcroImmune

by

OncoC4, a biopharmaceutical firm in its final phases of developing advanced cancer therapies, is merging with AcroImmune, a developer of immunotherapies for malignant tumors and inflammatory diseases. The merger produces first- and best-in-class immunotherapies. Drs. Yang Liu and Pan Zheng co-founded OncoC4 and AcroImmune, and they share a common shareholder base. The combined firm was … Read more

CorroHealth Acquired Revenue Cycle Management Business from Navient

by

CorroHealth has finalized its acquisition of the healthcare revenue cycle management (RCM) business from Navient’s Xtend Healthcare, significantly expanding its capabilities in revenue cycle management consultancy and technology. This strategic move enhances CorroHealth’s RCM offerings, introducing multichannel patient engagement capabilities that were previously missing from its suite of services. By adding these capabilities, CorroHealth strengthens … Read more

NanoVation Therapeutics Partners with Novo Nordisk to Develop Genetic Medicines for Cardiometabolic and Rare Diseases

by

Overview of the Deal:NanoVation Therapeutics has entered into a multi-year partnership with Novo Nordisk to develop cutting-edge genetic medicines that target cardiometabolic and rare diseases. Announced on September 18, 2024, this collaboration will leverage NanoVation’s long-circulating lipid nanoparticle (lcLNP™) technology, which enables RNA delivery to cells outside the liver, combined with Novo Nordisk’s expertise in … Read more